Physician profile
Maria E Falcon
NPI 1831183730
$2,340.38
in general payments reported to CMS, 2019-2025
23 companies · $737 in 2025
The $737 reported for 2025 was less than what a typical Allergy & Immunology provider received nationally (typical 2025 total: $1,138).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $91.59 · 2020: $85.81 · 2021: $93.00 · 2022: $96.17 · 2023: $903 · 2024: $333 · 2025: $737.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,923 · Education: $51.00.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,922.81 |
| Education | $51.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Genzyme Corporation | $490.63 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $362.53 | 2022-2025 | |
| Astrazeneca Pharmaceuticals Lp | $213.27 | 2020-2025 | Tezspire, Airsupra |
| Takeda Pharmaceuticals U.S.A., INC. | $190.52 | 2023-2025 | Cuvitru, Cinryze |
| Regeneron Healthcare Solutions, INC. | $174.84 | 2019-2025 | Dupixent |
| Biocryst US Sales Co., LLC | $130.63 | 2021-2023 | Orladeyo |
| Pharming Healthcare, INC. | $100.57 | 2022-2025 | Ruconest |
| Glaxosmithkline, LLC. | $95.65 | 2023 | Nucala |
| Csl Behring | $85.06 | 2020-2025 | Haegarda, Hizentra |
| Ars Pharmaceuticals Operations, INC. | $69.13 | 2025 | Neffy |
| Novartis Pharmaceuticals Corporation | $59.34 | 2025 | |
| Pfizer INC. | $47.74 | 2020-2023 | |
| Genentech USA, INC. | $43.63 | 2019 | |
| Aimmune Therapeutics, INC. | $43.41 | 2023 | |
| Optinose US, INC. | $42.29 | 2025 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Galderma Laboratories, L.P. | $40.74 | 2025 | Nemluvio |
| Grifols USA, LLC | $30.77 | 2023 | Xembify |
| Ionis Pharmaceuticals, INC. | $25.00 | 2025 | |
| Alk-Abello, INC | $22.78 | 2025 | Grastek, Odactra, Ragwitek |
| Blueprint Medicines Corporation | $20.62 | 2023 | Ayvakit |
| Amgen INC. | $18.02 | 2021 | |
| Kowa Pharmaceuticals America, INC. | $17.79 | 2025 | Zoryve |
| Phadia US INC. | $15.42 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Maria Falcon listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.